drugset / Trial / NCT00623402
Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma
Phase 2
Completed
55 enrolled
University Hospital Schleswig-Holstein
Dermatologic Cooperative Oncology Group · collab
NaSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of a combined treatment with Sorafenib (Nexavar®) and pegylated interferon-α-2b (PegIntron®) in patients with malignant melanoma in stage IV.
Timeline
- Start
- 2008-01
- Primary completion
- 2009-10
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Peginterferon alfa-2b | Protein / enzyme biologic | 3 ug/kg | Subcutaneous |
| Subject | Sorafenib | Small molecule | 400 mg | Oral |